title: Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
abstract: Rats treated with bezafibrate, a PPAR activator, gain less body weight and increase daily food intake. Previously, we have related these changes to a shift of thermogenesis from brown adipose tissue to white adipose tissue attributable to bezafibrate, which induces uncoupling proteins (UCP), UCP-1 and UCP-3, in rat white adipocytes. Nevertheless, UCP induction was weak, implying additional mechanisms in the change of energy homeostasis produced by bezafibrate. Here we show that bezafibrate, in addition to inducing UCPs, modifies energy homeostasis by directly inducing aco gene expression and peroxisomal fatty acid beta-oxidation in white adipose tissue. Further, bezafibrate significantly reduced plasma triglyceride and leptin concentrations, without modifying the levels of PPARgamma or ob gene in white adipose tissue. These results indicate that bezafibrate reduces the amount of fatty acids available for triglyceride synthesis in white adipose tissue.
authors.affiliation: Departamento Farmacología y Química Terapéutica, Facultad de Farmacia, Núcleo Universitario de Pedralbes, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Vázquez
authors.forename: N
authors.initials: N
authors.lastname: Roglans
authors.forename: A
authors.initials: A
authors.lastname: Cabrero
authors.forename: C
authors.initials: C
authors.lastname: Rodríguez
authors.forename: T
authors.initials: T
authors.lastname: Adzet
authors.forename: M
authors.initials: M
authors.lastname: Alegret
authors.forename: R M
authors.initials: RM
authors.lastname: Sánchez
authors.forename: J C
authors.initials: JC
authors.lastname: Laguna
mesh_terms: D042962:Acyl-CoA Oxidase; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood; D005227:Fatty Acids / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D020738:Leptin / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010088:Oxidoreductases / Q000378:metabolism*; D010100:Oxygen / Q000378:metabolism*; D020675:Peroxisomes / Q000378:metabolism*; D012313:RNA / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013696:Temperature; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D005227:Fatty Acids; D000960:Hypolipidemic Agents; D020738:Leptin; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D014280:Triglycerides; D012313:RNA; D002784:Cholesterol; D010088:Oxidoreductases; D042962:Acyl-CoA Oxidase; D010100:Oxygen; D001629:Bezafibrate